F

Fennec Pharmaceuticals Inc
TSX:FRX

Watchlist Manager
Fennec Pharmaceuticals Inc
TSX:FRX
Watchlist
Price: 10.77 CAD 1.03% Market Closed
Market Cap: 294.3m CAD

Intrinsic Value

The intrinsic value of one FRX stock under the Base Case scenario is 25.26 CAD. Compared to the current market price of 10.77 CAD, Fennec Pharmaceuticals Inc is Undervalued by 57%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

FRX Intrinsic Value
25.26 CAD
Undervaluation 57%
Intrinsic Value
Price
F
Worst Case
Base Case
Best Case

Valuation History
Fennec Pharmaceuticals Inc

Valuation History Unavailable

Historical valuation for FRX cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%
Compare FRX to

Fundamental Analysis

Company Overview
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about FENC?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Fennec Pharmaceuticals Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Fennec Pharmaceuticals Inc

Current Assets 44.1m
Cash & Short-Term Investments 26.6m
Receivables 12.9m
Other Current Assets 4.6m
Non-Current Assets 822k
Other Non-Current Assets 822k
Efficiency

Free Cash Flow Analysis
Fennec Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Fennec Pharmaceuticals Inc

Revenue
30.9m USD
Cost of Revenue
-3m USD
Gross Profit
27.9m USD
Operating Expenses
-39.9m USD
Operating Income
-12m USD
Other Expenses
-2.5m USD
Net Income
-14.4m USD
Fundamental Scores

FRX Profitability Score
Profitability Due Diligence

Fennec Pharmaceuticals Inc's profitability score is 43/100. The higher the profitability score, the more profitable the company is.

43/100
Profitability
Score

Fennec Pharmaceuticals Inc's profitability score is 43/100. The higher the profitability score, the more profitable the company is.

FRX Solvency Score
Solvency Due Diligence

Fennec Pharmaceuticals Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Negative Net Debt
Long-Term Solvency
55/100
Solvency
Score

Fennec Pharmaceuticals Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

FRX Price Targets Summary
Fennec Pharmaceuticals Inc

Wall Street analysts forecast FRX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for FRX is 17.71 CAD with a low forecast of 13.7 CAD and a high forecast of 21.36 CAD.

Lowest
Price Target
13.7 CAD
27% Upside
Average
Price Target
17.71 CAD
64% Upside
Highest
Price Target
21.36 CAD
98% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Fennec Pharmaceuticals Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for FENC is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

FENC Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one FRX stock?

The intrinsic value of one FRX stock under the Base Case scenario is 25.26 CAD.

Is FRX stock undervalued or overvalued?

Compared to the current market price of 10.77 CAD, Fennec Pharmaceuticals Inc is Undervalued by 57%.

Back to Top